Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (53 quarters reported)
$959M in Q2 2013 → $2.91B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| LM Liftoff Mobile | 20.9% | New | 25,315,646 | $608M |
| Dlocal | 20.9% | Unchanged | 46,656,695 | $606M |
| C Chime | 15.0% | Unchanged | 21,259,683 | $435M |
| A Alkami | 12.1% | Added 26% | 19,379,038 | $351M |
| Xp, Inc | 11.5% | Unchanged | 20,566,133 | $334M |
| P Pharvaris | 7.8% | Trimmed 18% | 6,550,757 | $227M |
| Seaport Therapeutics | 4.6% | New | 6,101,582 | $133M |
| Nurix Therapeutics | 2.5% | Trimmed 26% | 3,032,185 | $73.6M |
| Revolution Medicines | 2.3% | Trimmed 49% | 357,791 | $67M |
| PM Parabilis Medicines | 1.4% | New | 1,538,461 | $42.1M |
| Riskified | 0.9% | Unchanged | 5,324,998 | $26.8M |
| GC Grove Collaborative | 0.1% | Unchanged | 2,474,859 | $3.09M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| LM Liftoff Mobile | New | +25,315,646 | +$608M | 20.9% |
| Seaport Therapeutics | New | +6,101,582 | +$133M | 4.6% |
| European Wax Center | Exited | −13,110,492 | −$75.8M | — |
| A Alkami | Added | +4,041,543 | +$73.2M | 12.1% |
| Revolution Medicines | Trimmed | −350,000 | −$65.5M | 2.3% |
| Centessa Pharmaceuticals | Exited | −1,354,830 | −$53.8M | — |
| P Pharvaris | Trimmed | −1,480,495 | −$51.2M | 7.8% |
| PM Parabilis Medicines | New | +1,538,461 | +$42.1M | 1.4% |
| Nurix Therapeutics | Trimmed | −1,069,680 | −$26M | 2.5% |
| Webull | Exited | −50,816 | −$244K | — |
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Alignment Healthcare | Exited | −13,167,733 | −$260M | — |
| Revolution Medicines | Trimmed | −2,105,137 | −$205M | 3.2% |
| Centessa Pharmaceuticals | Trimmed | −4,762,885 | −$189M | 2.5% |
| A Alkami | Added | +3,346,015 | +$52.4M | 11.2% |
| Xp, Inc | Trimmed | −2,133,000 | −$40.6M | 18.2% |
| Nurix Therapeutics | Trimmed | −795,294 | −$12.3M | 3.0% |
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Akero Therapeutics | Exited | −5,733,989 | −$272M | — |
| Alignment Healthcare | Trimmed | −11,119,494 | −$220M | 9.1% |
| Nurix Therapeutics | New | +4,897,159 | +$92.9M | 3.2% |
| Centessa Pharmaceuticals | Trimmed | −3,564,103 | −$89.1M | 5.3% |
| Webull | Trimmed | −7,148,051 | −$55.5M | — |
| Royalty Pharma | Exited | −1,500,000 | −$52.9M | — |
| C Chime | Added | +2,050,923 | +$51.6M | 18.6% |
| Xp, Inc | Trimmed | −2,818,600 | −$46.1M | 12.9% |
| Revolution Medicines | Added | +338,500 | +$27M | 7.8% |
| Adagene | Exited | −3,782,339 | −$7.53M | — |
Showing the 10 largest of 11 changes.
quarter ended September 30, 2025 · filed November 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Alignment Healthcare | Trimmed | −19,706,096 | −$344M | 12.7% |
| Dlocal | Trimmed | −17,250,000 | −$246M | 20.0% |
| Revolution Medicines | New | +2,474,428 | +$116M | 3.5% |
| A Alkami | Added | +2,346,162 | +$58.3M | 8.9% |
| P Pharvaris | Added | +500,000 | +$12.5M | 6.0% |
| Webull | Added | +50,816 | +$752K | 3.2% |
| Adagene | Trimmed | −43,613 | −$86.8K | 0.2% |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| C Chime | New | +19,208,760 | +$663M | 18.3% |
| Alignment Healthcare | Trimmed | −17,000,000 | −$238M | 17.0% |
| Webull | New | +7,148,051 | +$85.5M | 2.4% |
| Xp, Inc | Trimmed | −4,100,000 | −$82.8M | 14.2% |
| I Immunocore | Exited | −1,261,684 | −$37.4M | — |
| Akero Therapeutics | Added | +500,000 | +$26.7M | 8.4% |
| Acelyrin | Exited | −2,695,327 | −$6.66M | — |
| W Wish | Exited | −609,616 | −$4.26M | — |
| Alumis | New | +1,297,530 | +$3.89M | 0.1% |
quarter ended March 31, 2025 · filed May 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Third Harmonic Bio | Exited | −3,372,323 | −$34.7M | — |
quarter ended December 31, 2024 · filed February 07, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Squarespace | Exited | −10,611,073 | −$493M | — |
| A Alkami | Trimmed | −5,875,000 | −$215M | 12.6% |
| Blend Labs | Exited | −19,132,440 | −$71.7M | — |
| Adagene | Added | +3,561,952 | +$7.09M | 0.3% |
| Third Harmonic Bio | Added | +413,561 | +$4.26M | 1.2% |
| GC Grove Collaborative | Added | +1,538,839 | +$2.14M | 0.1% |
| Acelyrin | Trimmed | −194,341 | −$610K | 0.3% |
quarter ended September 30, 2024 · filed November 12, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| A Alkami | Trimmed | −1,666,667 | −$52.6M | 13.9% |
| O Opendoor | Exited | −6,321,519 | −$11.6M | — |
Loading...
